About Alzamend Neuro™, Inc.
Alzamend Neuro™, Inc. (“Alzamend™”) is a biotechnology company dedicated to the research, development and commercialization of pharmaceuticals for the treatment and cure of Alzheimer’s disease. Alzamend Neuro™ is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) from the research and preclinical stage at the University of South Florida into the clinical stage and towards full commercialization. Alzamend Neuro™ has licensed both a patented mutant-peptide immunotherapeutic (CAO22W) for use as a treatment or vaccine and a lithium based ionic cocrystal therapy (LiProSal™) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with AD. There are no profound treatments today for Alzheimer’s disease. With CAO22W and LiProSal™, the Company believes that Alzamend™ can change that.
The number of Americans projected to be living with Alzheimer’s disease by the year 2050
The number of Americans projected currently living with Alzheimer’s disease in 2019
Every 65 Seconds
The estimate how often someone in the United States develops Alzheimer’s disease
Leading cause of death in the U.S.
The estimated number of seniors that will die with Alzheimer’s disease or other dementia by 2050
Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans
The estimated cost in 2019 of Alzheimer’s disease to the United States.
The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends
The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found
The estimated number of Americans age 65 and over that are afflicted in 2019 with Alzheimer’s disease
Are 2 ½ times more likely than men to develop Alzheimer’s disease in the United States
Estimated number of Americans that will have Alzheimer’s disease or other form of dementia by 2050 if a treatment or cure is not found